Cargando…

A Rare Case of Severe Manifestation of COVID-19 Infection Presenting as Immune-Related Thrombotic Thrombocytopenic Purpura With Multiorgan Involvement Treated With Plasmapheresis, Steroids, Rituximab, and Caplacizumab

Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy (TMA) caused by decreased activity of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13). Platelet-rich thrombi in small vessels lead to fragmentation of RBCs causing microangiopathic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mandyam, Saikiran, Fatmi, Syed S, Banzon, George, Kaur, Paramjit, Katamreddy, Yamini, Parghi, Devam, Farooq, Awais, Liaqat, Hamza, Basarakodu, Krishnamohan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Internal Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381864/ https://www.ncbi.nlm.nih.gov/pubmed/35989829 http://dx.doi.org/10.7759/cureus.26961

Ejemplares similares

Caplacizumab for thrombotic thrombocytopenic purpura
Publicado: (2020)

Caplacizumab for Acute Thrombotic Thrombocytopenic Purpura
por: Katsivalis, Katherine V., et al.
Publicado: (2021)

Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry
por: Agosti, Pasquale, et al.
Publicado: (2023)

Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura
por: Hanlon, Ashley, et al.
Publicado: (2020)

Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab
por: Sukumar, Senthil, et al.
Publicado: (2020)

Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura
por: Elverdi, Tugrul, et al.
Publicado: (2019)

Clinical Efficacy and Safety Profile of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
por: Maqsood, Muhammad Haisum, et al.
Publicado: (2019)

How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?
por: Zheng, Lucy, et al.
Publicado: (2023)

Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data
por: Gavriilaki, Eleni, et al.
Publicado: (2023)

More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura
por: Picod, Adrien, et al.
Publicado: (2022)

Immune‐mediated thrombotic thrombocytopenic purpura in a Jehovah’s Witness – Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab
por: Cardesa‐Salzmann, Teresa Marta, et al.
Publicado: (2022)

Delayed Thrombotic Complications in a Thrombotic Thrombocytopenic Purpura Patient Treated With Caplacizumab
por: Cilla, Nicolas, et al.
Publicado: (2020)

Outcomes in 1096 patients with severe thrombotic thrombocytopenic purpura before the Caplacizumab era
por: Van de Louw, Andry, et al.
Publicado: (2021)

Prolonged Exposure to Caplacizumab as Rescue Therapy in Refractory Immune Thrombotic Thrombocytopenic Purpura
por: Rodgers, George M, et al.
Publicado: (2023)

Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura
por: Bruzzese, Antonella, et al.
Publicado: (2023)

A Rare Presentation of Perivalvular Abscess and Infective Valve Endocarditis as Multiple Cerebral Septic Emboli Mimicking Ischemic Stroke
por: Mandyam, Saikiran, et al.
Publicado: (2023)

Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution
por: Logothetis, Constantine N., et al.
Publicado: (2021)

Caplacizumab Model‐Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura
por: Bergstrand, Martin, et al.
Publicado: (2021)

Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura
por: Izquierdo, Cristina Pascual, et al.
Publicado: (2022)

Brazilian experience with caplacizumab in acquired thrombotic thrombocytopenic purpura: outcomes of the expanded access program
por: de Oliveira Boechat, Tiago, et al.
Publicado: (2023)

Successful Treatment of Refractory Thrombotic Thrombocytopenic Purpura (TTP) With Caplacizumab: A Case Report
por: Pramanik, Debolina, et al.
Publicado: (2023)

Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab
por: Völker, Linus A., et al.
Publicado: (2020)

Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis
por: Djulbegovic, Mia, et al.
Publicado: (2022)

Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study
por: Knoebl, Paul, et al.
Publicado: (2019)

Myxedema Coma: A Grave Phenomenon Partially Reversed CKD Status With Treatment of Hypothyroidism
por: Mandyam, Saikiran, et al.
Publicado: (2023)

Idiopathic Relapsing Thrombotic Thrombocytopenic Purpura with Persistent ADAMTS13 Inhibitor Activity Treated Sequentially with Plasmapheresis, Rituximab, Cyclophosphamide and Splenectomy
por: Musa, Faisal, et al.
Publicado: (2015)

P1608: REAL-WORLD INSIGHTS ON THE MANAGEMENT OF IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP) WITH CAPLACIZUMAB IN BELGIUM
por: Dierickx, Daan, et al.
Publicado: (2023)

Cyclophosphamide-rescued plasmapheresis-unresponsive secondary thrombotic thrombocytopenic purpura caused by Sjögren's syndrome
por: Lin, Ting-Yun, et al.
Publicado: (2012)

Unmet needs in the management of immune‐mediated thrombotic thrombocytopenic purpura and the potential role of caplacizumab in the UK—A modified‐Delphi study
por: Scully, Marie, et al.
Publicado: (2022)

The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study
por: Miyakawa, Yoshitaka, et al.
Publicado: (2022)

Abnormal Longitudinal Strain in Takotsubo Cardiomyopathy: A Case Report
por: Kaur, Paramjit, et al.
Publicado: (2022)

Thyroid Storm with Multiorgan Failure Treated with Plasmapheresis
por: Miller, Ann, et al.
Publicado: (2019)

Mitomycin-Induced Thrombotic Thrombocytopenic Purpura Treated Successfully With Plasmapheresis and Steroid: A Case Report
por: Khaja, Misbahuddin, et al.
Publicado: (2022)

Thrombotic thrombocytopenic purpura treated with rituximab in systemic lupus erythematosus
por: Karimifar, Mansoor
Publicado: (2012)

Rituximab as first-line treatment for acquired thrombotic thrombocytopenic purpura
por: Chen, Haifei, et al.
Publicado: (2017)

Refractory Auto-Immune Thrombotic Thrombocytopenic Pupura Successfully Treated With Caplacizumab
por: Mellaza, Chloé, et al.
Publicado: (2020)

P1609: CAPLACIZUMAB THERAPY IN OLDER PATIENTS (≥60 YEARS) WITH IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP). RESULTS OF THE SPANISH TTP REGISTRY
por: Rubia, Javier DE LA, et al.
Publicado: (2023)

Ceftriaxone-Induced Thrombotic Thrombocytopenic Purpura Treated Successfully With Plasmapheresis and Eculizumab: A Rare Case Report
por: Qureshi, Zaheer A, et al.
Publicado: (2023)

Comparison of the efficacy and safety of caplacizumab versus placebo in thrombotic thrombocytopenic purpura: a meta-analysis and systematic review based on randomized controlled trials
por: Chen, Bin, et al.
Publicado: (2022)

Common variable immunodeficiency unmasked by treatment of immune thrombocytopenic purpura with Rituximab
por: Mogensen, Trine H, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5qouai81ecnlgosanp6tvemipo